- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07918898
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
October 31, 2026 updated by: Gan & Lee Pharmaceuticals.
A Phase I Study Comparing Pharmacokinetic/Pharmacodynamic Characteristics and Safety of Single Administration of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart in Healthy Participants
This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of GZR33 Injection and Insulin Aspart in healthy participants
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yunhong Wu
- Phone Number: 010-56456739
- Email: YunhongWu@ganlee.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Voluntarily signed the informed consent form (ICF), was amenable to subcutaneous injection, had fully understood the study content, procedures and potential adverse reactions, and was able to comply with the contraindications and restrictions specified in this protocol.
- Male, aged between 18 and 45 years (both inclusive) at the time of ICF.
Exclusion Criteria:
- Subjects with allergic diathesis, or a medical history of allergic diseases such as bronchial asthma and eczema.
- Subjects with abnormal findings for hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus antigen and antibody combined assay, or treponema pallidum antibody test at screening.
- Subjects who donated blood or had blood loss of ≥ 400 mL within 6 months prior to screening, or intend to donate blood during the study.
- Subjects with a history of drug abuse prior to screening, or with a positive drug abuse screening result at screening.
- Subjects with an average daily cigarette consumption of ≥5 cigarettes within 3 months prior to screening, or those who refuse to abstain from smoking throughout the study period.
- Subjects with a history of vasovagal syncope related to needles or blood, difficulty in blood collection, or intolerance to venipuncture for blood sampling.
- Subjects who are employees of the investigator or the study site, or family members of such employees or investigators, or subjects whom the investigator considers otherwise unsuitable for participation in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: GZR101 80 Injection
|
Single dose. Administered s.c. |
|
Experimental: GZR33 Injection + Insulin Aspart Injection
|
Single dose. Administered s.c. Single dose. Administered s.c. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AUCIAsp,0-6h
Time Frame: 0-6 hours after dosing
|
0-6 hours after dosing
|
|
AUC GZR33, 0-24h
Time Frame: 0-24 hours after dosing
|
0-24 hours after dosing
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AUCGZR33, 0-∞
Time Frame: 0-120 hours after dosing
|
0-120 hours after dosing
|
|
AUC IAsp, 0-∞
Time Frame: 0-120 hours after dosing
|
0-120 hours after dosing
|
|
Incidence of adverse events
Time Frame: 0-120 hours after dosing
|
0-120 hours after dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
October 29, 2026
Primary Completion (Estimated)
February 2, 2027
Study Completion (Estimated)
February 2, 2027
Study Registration Dates
First Submitted
October 27, 2026
First Submitted That Met QC Criteria
October 31, 2026
First Posted (Actual)
November 5, 2026
Study Record Updates
Last Update Posted (Actual)
November 5, 2026
Last Update Submitted That Met QC Criteria
October 31, 2026
Last Verified
October 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GZR101-T2D-103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.